Efficacy and Safety of FOLFOX in Advanced Gastric Cancer Initially Presenting With Disseminated Intravascular Coagulation

• Published in: In vivo (Athens) 2022-09, Vol.36 (5), p.2447-2452
• Main Authors: Takahashi, Naoki, Ando, Takayuki, Motoo, Iori, Sakumura, Miho, Ueda, Yuko, Kajiura, Shinya, Nakashima, Koji, Hosokawa, Ayumu, Ueda, Akira, Suzuki, Nobuhiro, Nakaya, Atsuko, Yasuda, Ichiro
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Disseminated Intravascular Coagulation - diagnosis; Disseminated Intravascular Coagulation - drug therapy; Disseminated Intravascular Coagulation - etiology; Humans; Organoplatinum Compounds - adverse effects; Stomach Neoplasms - complications; Stomach Neoplasms - drug therapy
• ISSN: 0258-851X; 1791-7549
• DOI: 10.21873/invivo.12979

Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis. Chemotherapy should be selected in consideration of hematological toxicities because these patients are at high risk of hemorrhagic complications. The leucovorin, fluorouracil, and oxaliplatin (FOLFOX) regimen is an effective and less toxic regimen for patients with AGC and poor performance status. The present study assessed overall survival of all patients receiving first-line chemotherapy with and without DIC using Kaplan-Meier methods and examined the clinicopathological factors, DIC parameters, response, and survival of five patients with AGC and DIC who received FOLFOX in the first-line setting between February 2017 and February 2020. Among the patients, four patients (80%) recovered from DIC after a median of 12 days of FOLFOX therapy (range=12-25), and their platelet count gradually increased within 1 week after the start of chemotherapy. The median progression-free survival and overall survival were 46 (range=22-296) and 115 days (range=83-324), respectively. No patients experienced adverse events necessitating treatment discontinuation, including gastrointestinal bleeding and thrombocytopenia. Moreover, all patients received second-line treatment after progression, and one patient exhibited improvement of DIC symptoms following nab-paclitaxel and ramucirumab treatment. FOLFOX therapy is well tolerated and effective in patients with AGC initially presenting with DIC and subsequent second-line treatment might be crucial for better prognosis.